Background: Cancer is one of the most important health problems of our age. Lung cancer is one of the most common cancers in Turkey as well as in the world. Diagnosis can be made late due to late detection of symptoms and findings. Cancer stem cells cause the initiation and progression of cancer. There is a risk of cancer recurrence due to cancer stem cells that cannot be destroyed. Therefore, it is important to detect cancer stem cells and prevent the proliferation of these stem cells.
Methods: In the Pathology Department of Pamukkale University Faculty of Medicine, 72 squamous cell carcinoma and 51 adenocarcinoma cases diagnosed with non-small cell lung cancer were retrospectively examined. Nucleostemin and CD133 expression levels were evaluated immunohistochemically in sections taken from cancerous tissue samples of the cases.
Results: Disease-free survival and tumor stages of the cases and immunohistochemical expression level were compared. Nucleostemin and CD133 expression was commonly observed in tumor tissue from both adenocarcinoma and squamous cell carcinoma cases.
Conclusion: Therefore, in line with the data we obtained, we think that both nucleostemin and CD133 can not be used as prognostic markers in non-small cell lung cancer.
Key words: Adenocarcinoma, Squamous cell cancer, CD133, Nucleostamin, Lung cancer
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
